Approximately 11 months after the viral sequence was published, two mRNA-based SARS-CoV-2 vaccines received emergency approval, demonstrating the potential of the technology. Vaccines for cancer and infectious diseases have proven effective thanks to low dosages, local delivery, and controlled protein expression. Recent advances have been made in cancer, Epstein-Barr virus, HIV, influenza, and Omicron-specific boosters as part of ongoing studies on mRNA-encoded proteins
Recent Comments